The estimated Net Worth of Steven C Gilman is at least $1.41 Milión dollars as of 4 September 2024. Steven Gilman owns over 5,000 units of Vericel Corp stock worth over $699,200 and over the last 10 years he sold VCEL stock worth over $495,231. In addition, he makes $220,085 as Independent Director at Vericel Corp.
Sign up
Steven Gilman VCEL stock SEC Form 4 insiders trading
Steven has made over 29 trades of the Vericel Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of VCEL stock worth $18,700 on 4 September 2024.
The largest trade he's ever made was buying 20,000 units of Vericel Corp stock on 27 July 2016 worth over $49,600. On average, Steven trades about 1,833 units every 34 days since 2015. As of 4 September 2024 he still owns at least 16,000 units of Vericel Corp stock.
You can see the complete history of Steven Gilman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Gilman biography
Dr. Steven C. Gilman, Ph.D., is an Independent Director of the company. Dr. Gilman is a director since January 2015, served as the Chairman of the board of directors and Chief Executive Officer of ContraFect Corporation until his retirement in April 2019. He previously served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals from September 2010 until its acquisition by Merck & Co., in January 2015. Prior to joining Cubist, Dr. Gilman served as Chairman of the board of directors and Chief Executive Officer of ActivBiotics, Inc., a privately-held biopharmaceutical company, from March 2004 to October 2007. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles, including Vice President and General Manager, Inflammation. Prior to Millennium, he was Group Director at Pfizer Global Research and Development and has also held scientific, business, and academic appointments at Wyeth Pharmaceuticals, Inc., Cytogen Corporation, Temple Medical School, and Connecticut College. Dr. Gilman currently serves on the boards of directors of ContraFect Corporation, SCYNEXIS, Inc. and Akebia Therapeutics, Inc. and on the board of directors and compensation committee of Momenta Pharmaceuticals, Inc. Dr. Gilman has previously served on the boards of directors of the Massachusetts Biotechnology Association and Keryx Biopharmaceuticals, Inc., prior to its merger with Akebia Therapeutics. Dr. Gilman has also held advisory roles on the Penn State University biotechnology board and the Northeastern University drug discovery board. Dr. Gilman received his B.A. in microbiology from Miami University of Ohio and a Ph.D. and M.S. degree in microbiology from Pennsylvania State University. Dr. Gilman performed his post-doctoral training at Scripps Clinic and Research Foundation.
What is the salary of Steven Gilman?
As the Independent Director of Vericel Corp, the total compensation of Steven Gilman at Vericel Corp is $220,085. There are 11 executives at Vericel Corp getting paid more, with Dominick Colangelo having the highest compensation of $5,385,530.
How old is Steven Gilman?
Steven Gilman is 67, he's been the Independent Director of Vericel Corp since 2017. There are 1 older and 13 younger executives at Vericel Corp. The oldest executive at Vericel Corp is Robert Zerbe, 69, who is the Independent Chairman of the Board.
What's Steven Gilman's mailing address?
Steven's mailing address filed with the SEC is C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Insiders trading at Vericel Corp
Over the last 10 years, insiders at Vericel Corp have traded over $9,831,645 worth of Vericel Corp stock and bought 890 units worth $10,297 . The most active insiders traders include Dominick Colangelo, Gerard J Michel a Kevin F Mclaughlin. On average, Vericel Corp executives and independent directors trade stock every 17 days with the average trade being worth of $567,401. The most recent stock trade was executed by Steven C Gilman on 4 September 2024, trading 5,000 units of VCEL stock currently worth $18,700.
What does Vericel Corp do?
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
What does Vericel Corp's logo look like?
Complete history of Steven Gilman stock trades at Akebia Therapeutics, ContraFect Corp, Momenta Pharmaceuticals, Scynexis Inc a Vericel Corp
Vericel Corp executives and stock owners
Vericel Corp executives and other stock owners filed with the SEC include:
-
Dominick Colangelo,
President, Chief Executive Officer, Director -
Michael Halpin,
Chief Operating Officer -
Dominick C. Colangelo Esq.,
CEO, Pres & Director -
Michael Halpin,
Chief Operating Officer -
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.,
Chief Medical Officer -
Dr. Jonathan M. Hopper,
Chief Medical Officer -
Sean C. Flynn,
VP, Gen. Counsel & Sec. -
Robert Zerbe,
Independent Chairman of the Board -
Alan Rubino,
Independent Director -
Kevin McLaughlin,
Independent Director -
Heidi Hagen,
Independent Director -
Steven Gilman,
Independent Director -
Paul Wotton,
Independent Director -
Sandra Pennell,
Principal Financial Officer and Principal Accounting Officer -
Jonathan Siegal,
Principal Accounting Officer, VP & Corp. Controller -
Roland DeAngelis,
Sr. VP of Commercial Operations -
Heidi Hassen,
VP of HR -
Patrick J. Fowler,
Sr. VP of Corp. Devel. & Strategy -
Eric Burns,
Exec. Director of Financial Planning and Analysis & Investor Relations -
Joseph Anthony Mara Jr.,
CFO, Principal Accounting Officer & Treasurer -
Capital Management Lp Conso...,
-
Daniel Orlando,
Chief Operating Officer -
Gerard J Michel,
CFO and VP, Corp. Development -
Nelson M Sims,
Director -
Lisa Wright,
-
Joseph Anthony Jr Mara,
Chief Financial Officer -
Jonathan Siegal,
Principal Accounting Officer -
Jonathan Mark Hopper,
Chief Medical Officer -
Sean C. Flynn,
Chief Legal Officer